Sendero Wealth Management LLC Has $3.99 Million Stake in Novo Nordisk A/S (NYSE:NVO)

Sendero Wealth Management LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 35.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 46,413 shares of the company's stock after buying an additional 12,142 shares during the period. Sendero Wealth Management LLC's holdings in Novo Nordisk A/S were worth $3,992,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. International Assets Investment Management LLC grew its position in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its stake in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock valued at $227,516,000 after purchasing an additional 1,593,303 shares during the period. Mediolanum International Funds Ltd bought a new stake in shares of Novo Nordisk A/S during the third quarter valued at approximately $98,765,000. Marshall Wace LLP boosted its position in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock worth $98,696,000 after buying an additional 689,441 shares during the period. Finally, Wellington Management Group LLP bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $42,017,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 0.4 %

Novo Nordisk A/S stock traded up $0.34 during mid-day trading on Thursday, hitting $83.26. The company's stock had a trading volume of 6,320,240 shares, compared to its average volume of 8,102,344. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a market cap of $373.61 billion, a PE ratio of 26.94, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The firm's 50 day moving average is $98.82 and its 200 day moving average is $117.93. Novo Nordisk A/S has a 52-week low of $80.05 and a 52-week high of $148.15.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. BMO Capital Markets cut their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research note on Monday, December 23rd. BNP Paribas upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, December 2nd. StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Buy" and an average price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.